Akari Therapeutics Plc SEC filings AKTX
Akari Therapeutics Plc has 743 filings in SEC EDGAR's recent list, going back to Apr 13, 2012. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jul 13, 2026 | — |
| EFFECT | Filing | Jul 7, 2026 | — |
| D | Filing | Jun 3, 2026 | — |
| RW | Filing | May 21, 2026 | — |
| NT 10-Q | Filing | May 18, 2026 | Mar 31, 2026 |
| EFFECT | Filing | Apr 15, 2026 | — |
| DRS | Filing | Apr 2, 2026 | — |
| EFFECT | Filing | Jan 29, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 27, 2026 | — |
| CORRESP | Letter to the SEC | Jan 27, 2026 | — |
| EFFECT | Filing | Dec 2, 2025 | — |
| CORRESP | Letter to the SEC | Dec 1, 2025 | — |
| D | Filing | Oct 24, 2025 | — |
| EFFECT | Filing | Jul 31, 2025 | — |
| CORRESP | Letter to the SEC | Jul 30, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 30, 2025 | — |
| EFFECT | Filing | May 14, 2025 | — |
| CORRESP | Letter to the SEC | May 12, 2025 | — |
| UPLOAD | Letter from the SEC | May 9, 2025 | — |
| NT 10-K | Filing | Mar 31, 2025 | Dec 31, 2024 |
| NT 10-Q | Filing | Nov 15, 2024 | Sep 30, 2024 |
| 425 | Filing | Oct 15, 2024 | — |
| EFFECT | Filing | Oct 11, 2024 | — |
| CORRESP | Letter to the SEC | Oct 9, 2024 | — |
| CORRESP | Letter to the SEC | Sep 30, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 26, 2024 | — |
| EFFECT | Filing | Sep 13, 2024 | — |
| CORRESP | Letter to the SEC | Sep 11, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 11, 2024 | — |
| NT 10-Q | Filing | Aug 15, 2024 | Jun 30, 2024 |
| 425 | Filing | Jun 4, 2024 | — |
| 425 | Filing | May 1, 2024 | — |
| 425 | Filing | Mar 11, 2024 | — |
| 425 | Filing | Mar 5, 2024 | — |
| 425 | Filing | Mar 5, 2024 | — |
| D | Filing | Jan 9, 2024 | — |
| EFFECT | Filing | Oct 26, 2023 | — |
| CORRESP | Letter to the SEC | Oct 25, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 24, 2023 | — |
| EFFECT | Filing | Oct 23, 2023 | — |
| EFFECT | Filing | Oct 23, 2023 | — |
| D | Filing | Oct 19, 2023 | — |
| EFFECT | Filing | Jun 6, 2023 | — |
| EFFECT | Filing | Jun 6, 2023 | — |
| EFFECT | Filing | Nov 8, 2022 | — |
| CORRESP | Letter to the SEC | Nov 7, 2022 | — |
| UPLOAD | Letter from the SEC | Oct 19, 2022 | — |
| D | Filing | Sep 27, 2022 | — |
| NT 20-F | Filing | Apr 29, 2022 | Dec 31, 2021 |
| EFFECT | Filing | Oct 1, 2021 | — |
| EFFECT | Filing | Oct 1, 2021 | — |
| EFFECT | Filing | Oct 1, 2021 | — |
| EFFECT | Filing | Oct 1, 2021 | — |
| EFFECT | Filing | Aug 31, 2021 | — |
| CORRESP | Letter to the SEC | Aug 30, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 23, 2021 | — |
| D | Filing | Jul 22, 2021 | — |
| EFFECT | Filing | Apr 30, 2021 | — |
| EFFECT | Filing | Apr 30, 2021 | — |
| EFFECT | Filing | Apr 30, 2021 | — |
| EFFECT | Filing | Apr 30, 2021 | — |
| EFFECT | Filing | Dec 31, 2020 | — |
| CORRESP | Letter to the SEC | Dec 30, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 30, 2020 | — |
| EFFECT | Filing | Sep 18, 2020 | — |
| EFFECT | Filing | Sep 18, 2020 | — |
| EFFECT | Filing | Sep 18, 2020 | — |
| EFFECT | Filing | Sep 18, 2020 | — |
| EFFECT | Filing | Jul 27, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 24, 2020 | — |
| CORRESP | Letter to the SEC | Jul 24, 2020 | — |
| EFFECT | Filing | May 11, 2020 | — |
| EFFECT | Filing | Apr 17, 2020 | — |
| EFFECT | Filing | Apr 16, 2020 | — |
| CORRESP | Letter to the SEC | Apr 15, 2020 | — |
| UPLOAD | Letter from the SEC | Mar 30, 2020 | — |
| D | Filing | Mar 11, 2020 | — |
| EFFECT | Filing | Oct 25, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 24, 2019 | — |
| CORRESP | Letter to the SEC | Oct 24, 2019 | — |
| EFFECT | Filing | Sep 6, 2019 | — |
| CORRESP | Letter to the SEC | Sep 6, 2019 | — |
| EFFECT | Filing | Sep 5, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 12, 2019 | — |
| D | Filing | Jul 12, 2019 | — |
| EFFECT | Filing | Apr 29, 2019 | — |
| EFFECT | Filing | Mar 4, 2019 | — |
| CORRESP | Letter to the SEC | Feb 27, 2019 | — |
| CORRESP | Letter to the SEC | Feb 11, 2019 | — |
| UPLOAD | Letter from the SEC | Dec 20, 2018 | — |
| CORRESP | Letter to the SEC | Dec 6, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 25, 2018 | — |
| NT 20-F | Filing | May 1, 2018 | Dec 31, 2017 |
| EFFECT | Filing | Feb 23, 2018 | — |
| CORRESP | Letter to the SEC | Feb 23, 2018 | — |
| UPLOAD | Letter from the SEC | Aug 24, 2017 | — |
| NT 10-Q | Filing | Nov 17, 2015 | Sep 30, 2015 |
| EFFECT | Filing | Oct 30, 2015 | — |
| CORRESP | Letter to the SEC | Oct 28, 2015 | — |
| UPLOAD | Letter from the SEC | Oct 27, 2015 | — |
| D | Filing | Sep 28, 2015 | — |
| RW | Filing | Mar 11, 2015 | — |
| EFFECT | Filing | Aug 20, 2014 | — |
| EFFECT | Filing | Mar 31, 2014 | — |
| EFFECT | Filing | Mar 31, 2014 | — |
| EFFECT | Filing | Mar 31, 2014 | — |
| CERTNAS | Auto-generated paper document | Jan 30, 2014 | — |
| EFFECT | Filing | Jan 30, 2014 | — |
| 8-A12B | Form 8-a12b | Jan 30, 2014 | — |
| EFFECT | Filing | Nov 6, 2013 | — |
| D | Filing | Sep 30, 2013 | — |
| EFFECT | Filing | Apr 16, 2013 | — |
| EFFECT | Filing | Apr 1, 2013 | — |
| EFFECT | Filing | Feb 1, 2013 | — |
| D | Filing | Feb 1, 2013 | — |
| CORRESP | Letter to the SEC | Jan 31, 2013 | — |
| UPLOAD | Letter from the SEC | Jan 9, 2013 | — |
| UPLOAD | Letter from the SEC | Dec 18, 2012 | — |
| D/A | Filing | Dec 13, 2012 | — |
| D | Filing | Dec 12, 2012 | — |
| EFFECT | Filing | Dec 7, 2012 | — |
| UPLOAD | Letter from the SEC | Nov 30, 2012 | — |
| 20FR12G/A | Filing | Nov 15, 2012 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2012 | — |
| 20FR12G/A | Amendment to form 20fr12g | Oct 29, 2012 | — |
| UPLOAD | Letter from the SEC | Oct 11, 2012 | — |
| 20FR12G/A | Amendment to form 20-f | Sep 27, 2012 | — |
| UPLOAD | Letter from the SEC | Sep 21, 2012 | — |
| CORRESP | Letter to the SEC | Aug 31, 2012 | — |
| 20FR12G | Form 20-f | Aug 31, 2012 | — |
| RW | Registration withdrawal | Aug 24, 2012 | — |
| UPLOAD | Letter from the SEC | Aug 22, 2012 | — |
| CORRESP | Letter to the SEC | Aug 8, 2012 | — |
| 20FR12G/A | Amendment no. 1 to form 20-f | Aug 8, 2012 | — |
| UPLOAD | Letter from the SEC | Jul 25, 2012 | — |
| 20FR12G | Form 20-f - registration statement - section 12(g) | Jun 28, 2012 | — |
| D | Filing | Apr 13, 2012 | — |
Showing 137 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AKTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Tampa, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1541157
- Former names
- Celsus Therapeutics Plc. (until Sep 15, 2015); Morria Biopharmaceuticals PLC (until Jun 20, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.